Edition:
United Kingdom

People: Adamas Pharmaceuticals Inc (ADMS.OQ)

ADMS.OQ on NASDAQ Stock Exchange Global Market

6.06USD
23 Aug 2019
Change (% chg)

$-0.07 (-1.14%)
Prev Close
$6.13
Open
$6.15
Day's High
$6.38
Day's Low
$6.03
Volume
76,849
Avg. Vol
96,618
52-wk High
$23.33
52-wk Low
$4.21

Rhodes, Jennifer 

Ms. Jennifer J. Rhodes serves as Chief Compliance Officer, General Counsel, Corporate Secretary, Chief Business Officer of the Company. Ms. Rhodes previously served as General Counsel at Medivation, Inc., a biopharmaceutical company, from June 2012 to September 2015, where she was responsible for Medivation’s legal matters, and also served as Corporate Secretary from April 2013 to September 2015 and as Chief Compliance Officer from July 2012 to October 2014. From May 2006 to June 2012, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., where she supported the U.S. Primary Care Business and its Primary Care Medicines Development Group, and served as a global product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer Inc., she was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP from October 2000 to April 2006. Ms. Rhodes received a J.D. from Wake Forest University School of Law and a B.A. in Economics from Newcomb College of Tulane University.

Basic Compensation

Total Annual Compensation, USD 328,526
Restricted Stock Award, USD 232,212
Long-Term Incentive Plans, USD --
All Other, USD 894,535
Fiscal Year Total, USD 1,455,270

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --